Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 1999

View Archived Issues

Small-molecule thrombopoietic compounds in development at Kyowa Hakko

Merck & Co.: Annual Report 1998

Pharmacokinetic evaluation of CDK inhibitor indicates need for short dosing interval

Multiple mechanisms of cytotoxic activity described for FR-901228

Genentech's NGF disappointing in phase III trial

Novel Roche peptides useful for bone disorders

IP receptor antagonists from Roche with potential as analgesic/antiinflammatory agents

FDA approves Fragmin for DVT after hip replacement surgery

Xenova presents novel topoisomerase inhibitor at AACR

Broad-spectrum antifungal agents in development at Merck

Warner-Lambert prepares naphthyridinone kinase and cell proliferation inhibitors

News from AACR: DNA topoisomerases as a preferred target for new anticancer drugs

Abbott's A-105972: new antimitotic agent presented at AACR meeting

News from AACR meeting: NCI evaluating new aminoflavone in preclinical studies

U.S. patent issued to Procyon for scar prevention therapy

Second-generation RAMBA selected by Janssen as development candidate

Pierre Fabre features topoisomerase inhibitor in several AACR presentations

Onyvax awarded grant for cancer vaccines

SR-271425: new thioxanthone with promising preclinical antitumor activity

Eye implant receives FDA approval for correcting mild myopia

Antitumor activity of intratumoral DTI-015 assessed in two rat models

Celebrex approved as arthritis treatment in Switzerland

Mitsui develops MS-247, a novel DNA minor groove-binding agent

D-24851 --a new tubulin-interacting agent with oral activity and improved therapeutic index

Chemical modification of magainin peptide results in effective, nontoxic antitumor compound

Karenitecin compound BNP-1350, a promising candidate for treating pediatric cancers

Synvisc approved, launched in South Africa

Parke-Davis team achieves excellent preclinical results with new EGF receptor TK inhibitor

TX-1123: a lead PK-inhibitory antitumor agent without mitochondrial toxicity

Preliminary analysis of Biomira's synthetic cancer vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...